Small Stocks, Big Money™

ConnectM (Nasdaq: CNTM) has secured a $725K rooftop solar contract in India through a strategic partnership with Zenith Energy, marking the company's international expansion and tapping into a market projected to grow at over 20% CAGR. Commissioned by a Coal India subsidiary, the 1.88 MW project leverages ConnectM’s AI-powered electrification platform and is set to drive near-term revenue while establishing a foothold in India’s $28B+ distributed energy sector.

Gorilla Technology (Nasdaq: GRRR) has firmly dismissed recent market manipulation claims, citing legal actions against those behind the allegations, and reaffirmed its commitment to shareholder value through continued share repurchases. Following its upcoming 2024 earnings release, the company and insiders intend to purchase shares, citing deep undervaluation and confidence in Gorilla’s AI-driven smart city and security solutions.

Calidi Biotherapeutics (NYSE American: CLDI) and City of Hope reported promising progress from their ongoing Phase 1 trial of CLD-101, a neural stem cell-based oncolytic virotherapy for recurrent high-grade glioma. With all 14 patients tolerating the treatment well, the trial is now enrolling at the highest dose level across top cancer centers including City of Hope, Stanford, and Northwestern. Backed by a $12M CIRM grant, the study showcases Calidi’s potential to revolutionize cancer treatment through stem cell-delivered virotherapy platforms.

Can-Fite BioPharma (NYSE American: CANF) has initiated a pivotal Phase 3 trial of Piclidenoson, its oral A3AR agonist, targeting moderate to severe plaque psoriasis—a $30B market by 2030. Backed by strong safety data and FDA/EMA-approved protocols, the global trial will assess key efficacy endpoints (PASI 75 and sPGA) over 16 weeks. With plans to expand into the U.S. and Canada, positive results could pave the way for regulatory filings in both regions.